COMPANY

Adial Pharmaceuticals

Adial Pharmaceuticals is listed on ClinicalTrials.gov as the lead sponsor of 1 study; the most recently updated is “Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms” (Phase 3, completed), in Alcohol Use Disorder. From public records Source · Oct 12, 2026

Keywords: AD04 (ondansetron)

Profile checked Oct 10, 2026

$3.6MRaised (2 yrs)1Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Form D reports $4.29M in warrant exercise value (filed Dec 3, 2025). SEC Form D 0001213900-25-117804 (Dec 3, 2025)
Evidence (1 event)
- Dec 3, 2025 · SEC Form D 0001213900-25-117804
  Name of Issuer: ADIAL PHARMACEUTICALS, INC.; CIK: 1513525; Address: Glen Allen, VA; Submission type: D; Filing date: 2025-12-03; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-28; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4285289; Total Amount Sold: 4285289; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jun 17, 2025 Raise Follow-on offering: $3.6M (total, as published), announced Jun 17, 2025. Source: SEC filing. source ↗
Feb 1, 2020 Trial start Phase 3: Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms source ↗

Funding

Raised: $3.6M. Last 2 years.

Jun 17, 2025 Follow-on offering: $3.6M (total, as published), announced Jun 17, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT04101227	Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms	Phase 3	Completed	Feb 1, 2020	Feb 18, 2022 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2025-12-03 Raise Private raise (SEC Form D): $4.3M sold; issuer “ADIAL PHARMACEUTICALS, INC.”. Verified from the SEC filing. SEC filing ↗
2025-05-14 Raise Private raise (SEC Form D): $4.8M sold; issuer “ADIAL PHARMACEUTICALS, INC.”. Verified from the SEC filing. SEC filing ↗